References
- Nora R., Abrams J. S., Tait N. S., Hiponia D. J., Silverman H. J. Myocardial toxic effects during recombinant interleukin-2 therapy. J. Natl. Cancer Inst. 1989; 81: 59–63, [PUBMED], [INFOTRIEVE]
- Gaynor E. R., Vitek L., Sticklin L., Creekmore S. P., Ferraro M. E., Thomas J. X., Fisher S. G., Fisher R. I. The hemodynamic effects of treatment with interleukin-2 and lymphokine activated killer cells. Ann. Intern. Med. 1988; 109: 953–958, [PUBMED], [INFOTRIEVE], [CSA]
- Okura Y., Yamamoto T., Goto S., Inomata T., Hirono S., Hanawa H., Feng, Wilson C. B., Kihara I., Izumi T., Shibata A., Aizawa Y., Seki S., Abo T. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J. Mol. Cell. Cardiol. 1997; 29(2)491–502, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Okura Y., Takeda K., Honda S., Hanawa H., Watanabe H., Kodama M., Izumi, Aizawa Y., Seki S., Abo T. Recombinant murine interleukin-12 facilitates induction of cardiac myosin-specific type 1 helper T cells in rats. Circ. Res. 1998; 82(10)1035–1042, [PUBMED], [INFOTRIEVE], [CSA]
- Samlowski W. E., Ward J. H., Craven C. M., Freedman R. A. Severe myocarditis following high dose interleukin-2 administration. Arch. Clin. Pathol. Lab. Med. 1989; 113: 838–841, [CSA]
- Schuchter L. M., Hendricks C. B., Holland K. H., Shelton B. K., Hutchins G. M., Baughman K. L., Ettinger D. S. Eosinophilic myocarditis associated with high dose interleukin-2 therapy. Am. J. Med. 1990; 88: 439–440, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kragle A. H., Travis W. D., Feinberg L., Pittaluga S., Striker L. M., Roberts W. C., Lotze M. T., Yang J. J., Rosenberg S. A. Pathologic findings associated with interleukin-2 based immunotherapy for cancer: a postmortem study of 19 patients. Human Pathol. 1990; 21: 493–502, [CROSSREF]
- Pisani B., Taylor D. O., Mason J. Inflammatory myocardial diseases and cardiomyopathies. Am. J. Med. 1997; 102: 459–469, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fisher R. I., Rosenberg S. A., Fyfe G. Long term update for high dose bolus recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 2000; 6(Suppl. 1)S55–S57, [PUBMED], [INFOTRIEVE]
- Fyfe G., Fisher R. I., Rosenberg S. A., Sznol M., Parkinson D. R., Louie A. C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy. J. Clin. Oncol. 1995; 13: 688–696, [PUBMED], [INFOTRIEVE]
- Atkins M. B., Kunkel L., Sznol M., Rosenberg S. A. High dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long term survival update. Cancer J. Sci. Am. 2000; 6(Supplement)S11–S14, [PUBMED], [INFOTRIEVE]
- Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A. High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999; 17(7)2105–2116, [PUBMED], [INFOTRIEVE]